This article is more than 5 years old. Information may no longer be current.

10 takeaways from this year’s ESMO Congress

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Society for Medical Oncology Congress featured three presidential symposia and 47 late-breaking abstracts within this year’s theme of “From Disease Treatment to Patient Care.”

HemOnc Today presents 10 takeaways in cancer research from the meeting.

• The addition of irinotecan to FOLFOX chemotherapy and bevacizumab (Avastin, Genentech) improved response rates and prolonged PFS for the first-line treatment of advanced colorectal cancer, according to results of the randomized phase 2 CHARTA trial. Read more.
• Adjuvant treatment with sunitinib (Sutent, Pfizer) significantly prolonged DFS compared with placebo among patients with locoregional clear-cell renal cell carcinoma at high risk for tumor recurrence after nephrectomy. Read more.
• Results from the CABOSUN trial may be a “game changer” in the first-line treatment of metastatic renal cell carcinoma, Sumanta K. Pal, MD, a HemOnc Today Editorial Board member and medical oncologist at City of Hope Comprehensive Cancer Center, said. Watch here.
• Adjuvant therapy with ipilimumab (Yervoy, Bristol-Myers Squibb) significantly extended survival compared with placebo among patients who underwent complete resection for stage III melanoma at high risk for relapse. Read more.
• Corey J. Langer, MD, director of the thoracic oncology program at Abramson Cancer Center of University of Pennsylvania, discusses positive results from cohort G of the KEYNOTE-021 study. Watch here.
• Second-line nivolumab (Opdivo, Bristol-Myers Squibb) monotherapy demonstrated clinically meaningful efficacy in patients with metastatic or surgically unresectable, locally advanced urothelial cancer. Read more.
• The addition of nintedanib (Ofev, Boehringer Ingelheim) to best supportive care appeared safe and significantly extended PFS in patients with metastatic colorectal cancer that is refractory to standard therapies, according to results of the phase 3 LUME-colon 1 study. Read more.
• Fulvestrant significantly prolonged PFS compared with anastrozole among women with hormone receptor–positive advanced breast cancer. Read more.
• Nivolumab did not significantly extend PFS compared with investigator’s choice of platinum-doublet chemotherapy in patients with stage IV or recurrent PD-L1–positive non–small cell lung cancer, according to results of the phase 3 CheckMate 026 trial. Read more.
• The addition of olaparib (Lynparza, AstraZeneca) to paclitaxel demonstrated a trend toward an OS benefit in patients with advanced gastric cancer independently of ATM protein status, according to results of the phase 3 GOLD trial. Read more.